Analysis of Growth Factors in Patients Undergoing Lucentis or Avastin Injections for Diabetic Macular Edema and Exudative Macular Degeneration.

Trial Profile

Analysis of Growth Factors in Patients Undergoing Lucentis or Avastin Injections for Diabetic Macular Edema and Exudative Macular Degeneration.

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Dec 2014

At a glance

  • Drugs Bevacizumab (Primary) ; Ranibizumab (Primary)
  • Indications Diabetic macular oedema; Wet macular degeneration
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 19 Jun 2012 Actual initiation date (Nov 2011) added and planned patient number is 40 as reported by ClinicalTrials.gov.
    • 19 Jun 2012 Planned end date (Jan 2014) added as reported by ClinicalTrials.gov.
    • 22 Nov 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top